Friday, June 20, 2025 6/20/2025

Analysis of T-cell antigen diversity by deep sequencing

Award Number: R21CA226321
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2018
PERIOD OF PERFORMANCE END DATE: 03/31/2020

Group Awards By:

View Award Description

Analysis of T-cell antigen diversity by deep sequencing - PROJECT SUMMARY/ABSTRACT T-cells are among the most potent and precise immune cells in the body’s defensive arsenal. T-cell receptors (TCRs), that are unique to each T-cell clone, provide antigen recognition capability to cytolytic T cells (CTLs), which allows for targeted killing of infected or cancerous cells. Healthy cells are recognized as “self” and do not trigger a killing response from CTLs. It is the repertoire of all T-cells and their respective TCRs that collectively provides immune protection against threats posed by foreign pathogens or cancerous cells in the body. TCRs are encoded by highly variable genes expressed in T-cells that result in an abundant diversity of TCRs in humans, which can now be routinely decoded by DNA sequence analysis. However, there is still no tractable method to determine exactly which antigens are being recognized by the TCR expressed by a given T-cell of interest. This is important because it is the knowledge of antigens that is necessary to understand cellular immunology at its most fundamental level. Further, in a practical sense, the identity of T- cell antigens is necessary to design new immune interventions, including vaccines, biopharmaceuticals, or cell-based therapies. Immune-based therapies for complex pathogens such as HIV, malaria and tuberculosis require optimal T-cell antigens for specificity, as do many therapies for cancer, where our knowledge of antigens remains rudimentary. In the current proposal, we aim to leverage DNA sequencing technology to develop a method to discover DNA sequences that encode antigens recognized by T-cells of interest. This will be accomplished by making DNA libraries encoding large sets of possible antigens, transferring the DNA libraries into laboratory cell lines that will express the encoded antigens at their cell surfaces, screening these cells against a T-cell population of interest, isolating the specific target cells that were recognized by T-cells, and then identifying the antigens carried within the recovered target cells using DNA sequencing. This new technology will be reduced to practice using known, model T-cells and antigens and, once optimized, it will be mobilized toward the comprehensive mapping of T-cell/antigen interactions in health and disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$26,424 )
2025	2018	PROVINCIAL HEALTH SERVICES AUTHORITY	600 10TH AVE W	VANCOUVER	BC			CAN	Cancer Treatment Research	000	2	10/1/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$26,424
														Subtotal = -$26,424

Issue Date FY: 2022 ( Subtotal = $1 )
2022	2018	BRITISH COLUMBIA CANCER AGENCY BRANCH	600 10TH AVE W	VANCOUVER	BC			CAN	Cancer Treatment Research	000	1	9/26/2022	NEW	$1
														Subtotal = $1

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	PROVINCIAL HEALTH SERVICES AUTHORITY	600 10TH AVE W	VANCOUVER	BC			CAN	Cancer Treatment Research	000	3	7/12/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	BRITISH COLUMBIA CANCER AGENCY BRANCH	600 10TH AVE W	VANCOUVER	BC	V5Z 4E6		CAN	Cancer Treatment Research	000	1	11/20/2019	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $102,056 )
2019	2019	PROVINCIAL HEALTH SERVICES AUTHORITY	600 10TH AVE W	VANCOUVER	BC	V5Z 4E6		CAN	Cancer Treatment Research	002	3	3/25/2019	NON-COMPETING CONTINUATION	$102,056
2019	2018	BRITISH COLUMBIA CANCER AGENCY BRANCH	600 10TH AVE W	VANCOUVER	BC	V5Z 4E6		CAN	Cancer Treatment Research	000	1	12/19/2018	NEW	-$77,856
2019	2018	PROVINCIAL HEALTH SERVICES AUTHORITY	600 10TH AVE W	VANCOUVER	BC	V5Z 4E6		CAN	Cancer Treatment Research	001	2	12/19/2018	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$77,856
														Subtotal = $102,056

Issue Date FY: 2018 ( Subtotal = $107,091 )
2018	2018	BRITISH COLUMBIA CANCER AGENCY BRANCH	600 10TH AVE W	VANCOUVER	BC	V5Z 4E6		CAN	Cancer Treatment Research	000	1	3/15/2018	NEW	$107,091
														Subtotal = $107,091

Grand Total All Awards = $182,723

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Analysis of T-cell antigen diversity by deep sequencing

Award Number: R21CA226321

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2018

PERIOD OF PERFORMANCE END DATE: 03/31/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer